|
|
Article: Liponex announces U.S. patent allowance and Phase I trial results for drug that boosts good cholesterol - Early results indicate CRD5 increases HDL levels by an average of 18% in two weeks.
- Article from:
- PR Newswire
- Article date:
- October 19, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OTTAWA, Oct. 19 /PRNewswire/ -- Liponex Inc., a biopharmaceutical company specializing in the development of charge regulating drugs (CRD), today announced that it has been granted a U.S. patent allowance for its first product, CRD5, a novel drug in development for the treatment of cholesterol and atherosclerosis. The company also announced the results of Phase I human trials of CRD5.
The Phase I trials, conducted at the University of Ottawa Heart Institute on 56 volunteers over a two-week dosing period, were designed to test the safety of CRD5. No negative health effects were observed and the trial results confirmed that the drug is safe and well-tolerated.
...
Related newspaper, magazine, and journal articles:
|
|
Article: BREAKING STORY: Pregnant Woman With Heart Disease ...
PR Newswire;
January 30, 2003 ;
622 words
... ... beginning of her current pregnancy, she showed signs of heart disease. The opening in her aorta -- three to four centimeters ... 7:30 a.m. in the Long Beach Memorial Medical Center Heart Institute operating room, where sophisticated cardiac technology ...
|
|